116 related articles for article (PubMed ID: 11340902)
1. Neoadjuvant therapy for non-small cell lung cancer.
Gandara DR; Lara PN; Goldberg Z; Roberts P; Lau DH
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S5-9. PubMed ID: 11340902
[TBL] [Abstract][Full Text] [Related]
2. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
4. The current status of docetaxel for advanced non-small cell lung cancer.
Green MR
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
[TBL] [Abstract][Full Text] [Related]
5. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
6. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Fossella FV
Semin Oncol; 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PubMed ID: 10585004
[TBL] [Abstract][Full Text] [Related]
8. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
Mattson K
Semin Oncol; 1999 Jun; 26(3 Suppl 10):25-8. PubMed ID: 10437748
[TBL] [Abstract][Full Text] [Related]
10. Sequential combined modality therapy for stage III non-small cell lung cancer.
Vokes EE
Hematol Oncol Clin North Am; 1990 Dec; 4(6):1133-42. PubMed ID: 1962780
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
Armand JP
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():223-30. PubMed ID: 10895158
[TBL] [Abstract][Full Text] [Related]
12. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
13. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Hong WK
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):9-15. PubMed ID: 12108903
[TBL] [Abstract][Full Text] [Related]
14. [What is the value of neoadjuvant therapy in bronchial carcinoma?].
Digel W; Brethner L; Hasse J
Zentralbl Chir; 2000; 125(4):315-8. PubMed ID: 10829310
[TBL] [Abstract][Full Text] [Related]
15. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Fossella FV
Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel in advanced non-small cell lung cancer.
Wakelee H; Ramalingam S; Belani CP
Expert Rev Anticancer Ther; 2005 Feb; 5(1):13-24. PubMed ID: 15757434
[TBL] [Abstract][Full Text] [Related]
17. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Gandara DR; Edelman MJ; Lau D
Semin Oncol; 1999 Jun; 26(3 Suppl 10):3-7. PubMed ID: 10437743
[TBL] [Abstract][Full Text] [Related]
19. Single agents in the second-line treatment of non-small cell lung cancer.
Belani CP
Semin Oncol; 1998 Jun; 25(3 Suppl 8):10-4. PubMed ID: 9704670
[TBL] [Abstract][Full Text] [Related]
20. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma.
Koukourakis MI; Bahlitzanakis N; Froudarakis M; Giatromanolaki A; Georgoulias V; Koumiotaki S; Christodoulou M; Kyrias G; Skarlatos J; Kostantelos J; Beroukas K
Br J Cancer; 1999 Aug; 80(11):1792-6. PubMed ID: 10468298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]